BBK Makes Mobile App Suite Available Free of Charge
BBK Worldwide, a clinical trial marketing firm announced it is making the availability of its mobile apps My Clinical Study Buddy®for patients and My Protocol Pal® for investigators free of charge throughout 2015.
BBK Makes Mobile App Suite Available Free of Charge
BBK Worldwide, a clinical trial marketing firm announced it is making the availability of its mobile apps My Clinical Study Buddy® for patients and My Protocol PalSM for investigators free of charge throughout 2015. BBK’s mobile apps are built on its cloud-based content management engine, TrialCentralNetSM (TCN®), to help companies reduce enrollment timelines and provide insight into key patient recruitment pressure points. What’s more, BBK’s engagement solutions, RSG® Card and RSG® Arrive are also available through TCN for a seamless connection to My Clinical Study Buddy®. These offerings allow the study community to more easily reimburse and arrange travel for relevant studies, a major and often overlooked bottleneck for sites and sponsors – especially with the complex travel and reimbursements inherent in rare disease trials.
Read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
